Key result
Saxagliptin increases heart failure hospitalization risk ~27% vs. placebo in type 2 diabetes.
Why the study?
Few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point in patients with type 2 diabetes and cardiovascular risk.
Does saxagliptin reduce the composite of cardiovascular death, myocardial infarction, or ischemic stroke in patients with type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events?
RCT (n=16,492)
randomized
Does saxagliptin reduce the composite of cardiovascular death, myocardial infarction, or ischemic stroke in patients with type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events?
In patients with type 2 diabetes at high cardiovascular risk, saxagliptin increased the risk of heart failure hospitalization, especially among those with prior heart failure, chronic kidney disease, or elevated NT-proBNP.
Answers are grounded in this paper and cite their sources.
Saxagliptin increases heart failure hospitalization risk in high-CV-risk type 2 diabetes; challenges DPP-4 inhibitor safety assumptions and warrants avoidance in prior heart failure.
BACKGROUND: Diabetes mellitus and heart failure frequently coexist. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point. METHODS AND RESULTS: A total of 16 492 patients with type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events were randomized to saxagliptin or placebo (mean follow-up, 2.1 years). The primary end point was the composite of cardiovascular death, myocardial infarction, or ischemic stroke. Hospitalization for heart failure was a predefined component of the secondary end point. Baseline N-terminal pro B-type natriuretic peptide was measured in 12 301 patients. More patients treated with saxagliptin (289, 3.5%) were hospitalized for heart failure compared with placebo (228, 2.8%; hazard ratio, 1.27; 95% confidence intercal, 1.07-1.51; P=0.007). Corresponding rates at 12 months were 1.9% versus 1.3% (hazard ratio, 1.46; 95% confidence interval, 1.15-1.88; P=0.002), with no significant difference thereafter (time-varying interaction, P=0.017). Subjects at greatest risk of hospitalization for heart failure had previous heart failure, an estimated glomerular filtration rate ≤60 mL/min, or elevated baseline levels of N-terminal pro B-type natriuretic peptide. There was no evidence of heterogeneity between N-terminal pro B-type natriuretic peptide and saxagliptin (P for interaction=0.46), although the absolute risk excess for heart failure with saxagliptin was greatest in the highest N-terminal pro B-type natriuretic peptide quartile (2.1%). Even in patients at high risk of hospitalization for heart failure, the risk of the primary and secondary end points were similar between treatment groups. CONCLUSIONS: In the context of balanced primary and secondary end points, saxagliptin treatment was associated with an increased risk or hospitalization for heart failure. This increase in risk was highest among patients with elevated levels of natriuretic peptides, previous heart failure, or chronic kidney disease. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01107886.
No takes yet. Share an insight, caveat, or question.
Scirica et al. (2014) conducted an RCT in Type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events (n=16,492). Saxagliptin vs. Placebo was evaluated on Hospitalization for heart failure (HR 1.27, 95% CI 1.07-1.51, p=0.007). Saxagliptin increased the risk of hospitalization for heart failure compared with placebo in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: